Bicarbonate

Bicarbonate

SCHEMBL20888

N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.55
SLCO1B1 Q9Y6L6 1/20 0.55
PDE4A P27815 1/20 0.48
PAX8 Q06710 1/20 0.46
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
AKR1B1 P15121 1/20 0.36
KDM4E B2RXH2 2/20 0.34
OR51E2 Q9H255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL7572044 0.94 USP2 (0.53) USP2SLCO1B1PDE4APAX8LMNA
Acetic Acid SCHEMBL489053 0.94 USP2 (0.53) USP2SLCO1B1PDE4APAX8LMNA
Acetic Acid SCHEMBL8370700 0.94 USP2 (0.53) USP2SLCO1B1PDE4APAX8LMNA
Acetic Acid SCHEMBL403998 0.94 USP2 (0.53) USP2SLCO1B1PDE4APAX8LMNA
SCHEMBL2228073 0.94 LMNA (0.52) USP2SLCO1B1PDE4APAX8LMNA
SCHEMBL1548302 0.94 LMNA (0.52) USP2SLCO1B1PDE4APAX8LMNA
SCHEMBL8586304 0.94 LMNA (0.52) USP2SLCO1B1PDE4APAX8LMNA
SCHEMBL420278 0.94 LMNA (0.52) USP2SLCO1B1PDE4APAX8LMNA
SCHEMBL22963142 0.94 LMNA (0.52) USP2SLCO1B1PDE4APAX8LMNA
SCHEMBL17493340 0.94 LMNA (0.52) USP2SLCO1B1PDE4APAX8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10857176-B2 Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan Oligo Médic Inc. (CA) 2020-12-08 US claimed
US-20190247421-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN OLIGO MEDIC INC. 2019-08-15 US claimed
CN-103189435-B Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC. (CA) 2016-02-17 CN claimed
EP-2609149-B1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC (CA) 2015-08-12 EP claimed
US-8784850-B2 Highly biocompatible dual thermogelling chitosan/glucosamine salt composition OLIGO MEDIC INC (CA) 2014-07-22 US claimed
US-20130266549-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITION OLIGO MEDIC INC (CA) 2013-10-10 US claimed
US-8506972-B2 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC (CA) 2013-08-13 US claimed
EP-2609149-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS Oligo Medic Inc. (CA) 2013-07-03 EP claimed
CN-103189435-A Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC 2013-07-03 CN claimed
US-20120052012-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC. (CA) 2012-03-01 US claimed
WO-2012024785-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC. (CA) 2012-03-01 WO claimed
US-10857176-B2 Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan Oligo Médic Inc. (CA) 2020-12-08 US disclosed
US-20190247421-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN OLIGO MEDIC INC. 2019-08-15 US disclosed
US-20170216341-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN OLIGO MÉDIC INC (CA) 2017-08-03 US disclosed
CN-103189435-B Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC. (CA) 2016-02-17 CN disclosed
CN-102415596-A Carbonated beverage UNIV NINGBO 2012-04-18 CN disclosed
US-20120052012-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC. (CA) 2012-03-01 US disclosed
WO-2012024785-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC. (CA) 2012-03-01 WO disclosed
US-6589555-B2 Effervescent vitaceutical compositions and related methods PANDYA MAHENDRA (US) 2003-07-08 US disclosed
US-20010051134-A1 Effervescent vitaceutical compositions and related methods PANDYA MAHENDRA (US) 2001-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10857176-B2 Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan CD44, IDUA, FUT6 USP2 628/4885SLCO1B1 1828/4885PDE4A 4358/4885
US-20170216341-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN CD44, IDUA, FUT6 USP2 628/4885SLCO1B1 1828/4885PDE4A 4358/4885
US-20190247421-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN CD44, IDUA, FUT6 USP2 628/4885SLCO1B1 1828/4885PDE4A 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.